Press release 2 September 2016 at 1.00 p.m. EEST Orion Corporation announced today that it has entered into a collaboration agreement with Menarini Group, for the co-marketing of budesonide-formoterol ...
Orion Corporation has received Irish and Hungarian marketing authorisation for Bufomix Easyhaler®, an inhaled budesonide-formoterol combination product indicated for asthma and chronic obstructive ...
In conclusion, the Easyhaler ® more closely demonstrates the characteristics of an ‘ideal inhaler' than its competitors (consistent fine particle dose, performance regardless of inspiration rate, ...
Pediapharm Inc. ("Pediapharm" or the "Company") (TSX VENTURE:PDP) announces that Health Canada has upheld the May 2015 Notice of Deficiency - Withdrawal Letter regarding Easyhaler Budesonide, without ...
Pediapharm Inc. (TSX VENTURE:PDP) ("Pediapharm" or the "Company") announced today that it has received a Notice of Deficiency - Withdrawal Letter from Health Canada regarding its New Drug Submission ...
ORION CORPORATION STOCK EXCHANGE RELEASE 21 MARCH 2013 at 6.25 p.m. EET Orion Corporation has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the ...
GPs could prescribe budesonide inhalers as a Covid treatment ‘on a case-by-case basis’ although it is not ‘at this point in time’ being ‘recommended for routine use’, the Government has said. The ...
a strong partner focusing on respiratory therapy area. The collaboration accelerates the good momentum we have for Easyhaler products in Europe and strengthens Orion`s strategic objective to become a ...
Press release 2 September 2016 at 1.00 p.m. EEST Orion Corporation announced today that it has entered into a collaboration agreement with Menarini Group, for the co-marketing of budesonide-formoterol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results